The DOI matches its Crossref record; 141 of the 141 references it cites were found in a registry or an index.
Nitrogen Containing Heterocycles as Anticancer Agents: A Medicinal Chemistry Perspective
Open accessAbstract
Cancer is one of the major healthcare challenges across the globe. Several anticancer drugs are available on the market but they either lack specificity or have poor safety, severe side effects, and suffer from resistance. So, there is a dire need to develop safer and target-specific anticancer drugs. More than 85% of all physiologically active pharmaceuticals are heterocycles or contain at least one heteroatom. Nitrogen heterocycles constituting the most common heterocyclic framework. In this study, we have compiled the FDA approved heterocyclic drugs with nitrogen atoms and their pharmacological properties. Moreover, we have reported nitrogen containing heterocycles, including pyrimidine, quinolone, carbazole, pyridine, imidazole, benzimidazole, triazole, β-lactam, indole, pyrazole, quinazoline, quinoxaline, isatin, pyrrolo-benzodiazepines, and pyrido[2,3-d]pyrimidines, which are used in the treatment of different types of cancer, concurrently covering the biochemical mechanisms of action and cellular targets.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21660 · Cited by 108,699
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21492 · Cited by 84,109
ChEMBL: towards direct deposition of bioassay data
Mendez, D., Gaulton, A., Bento, A. P., Chambers, J., De Veij, M., Félix, E., Magariños, M. P., Mosquera, J. F., Mutowo, P., Nowotka, M., et al. (2019) · Nucleic Acids Research · doi:10.1093/nar/gky1075 · Cited by 2,372
β-Lactams and β-Lactamase Inhibitors: An Overview
Bush, K., & Bradford, P. A. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a025247 · Cited by 1,412
Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3 -Mutated AML
Perl, A. E., Martinelli, G., Cortes, J. E., Neubauer, A., Berman, E., Paolini, S., Montesinos, P., Baer, M. R., Larson, R. A., Ustun, C., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1902688 · Cited by 1,287
Prescribed drugs containing nitrogen heterocycles: an overview
Heravi, M. M., & Zadsirjan, V. (2020) · RSC Advances · doi:10.1039/d0ra09198g · Cited by 1,194
1,2,3-Triazole-containing hybrids as leads in medicinal chemistry: A recent overview
Bozorov, K., Zhao, J., & Aisa, H. A. (2019) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2019.07.005 · Cited by 854
Martins, P., Jesus, J., Santos, S., Raposo, L., Roma-Rodrigues, C., Baptista, P., & Fernandes, A. (2015) · Molecules · doi:10.3390/molecules200916852 · Cited by 716
Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development
Shen, G., Zheng, F., Ren, D., Du, F., Dong, Q., Wang, Z., Zhao, F., Ahmad, R., & Zhao, J. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0664-7 · Cited by 658
FDA Drug Approval Summary: Gefitinib (ZD1839) (Iressa®) Tablets
Cohen, M. H., Williams, G. A., Sridhara, R., Chen, G., & Pazdur, R. (2003) · The Oncologist · doi:10.1634/theoncologist.8-4-303 · Cited by 581
Pyrimidine as Constituent of Natural Biologically Active Compounds
Lagoja, I. (2005) · Chemistry & Biodiversity · doi:10.1002/cbdv.200490173 · Cited by 544
Kim, G., Ison, G., McKee, A. E., Zhang, H., Tang, S., Gwise, T., Sridhara, R., Lee, E., Tzou, A., Philip, R., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0887 · Cited by 528
Irinotecan: 25 years of cancer treatment
Bailly, C. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.104398 · Cited by 456
FDA Drug Approval Summary: Erlotinib (Tarceva®) Tablets
Cohen, M. H., Johnson, J. R., Chen, Y.-F., Sridhara, R., & Pazdur, R. (2005) · The Oncologist · doi:10.1634/theoncologist.10-7-461 · Cited by 445
Guo, Y., Liu, Y., Hu, N., Yu, D., Zhou, C., Shi, G., Zhang, B., Wei, M., Liu, J., Luo, L., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00687 · Cited by 359
Afatinib: First Global Approval
Dungo, R. T., & Keating, G. M. (2013) · Drugs · doi:10.1007/s40265-013-0111-6 · Cited by 329
Osimertinib: First Global Approval
Greig, S. L. (2016) · Drugs · doi:10.1007/s40265-015-0533-4 · Cited by 322
Ueber die Einwirkung des Ammoniaks auf Glyoxal
Debus, H. (1858) · Justus Liebigs Annalen der Chemie · doi:10.1002/jlac.18581070209 · Cited by 308
Ryan, Q., Ibrahim, A., Cohen, M. H., Johnson, J., Ko, C.-W., Sridhara, R., Justice, R., & Pazdur, R. (2008) · The Oncologist · doi:10.1634/theoncologist.2008-0816 · Cited by 307
Novel Biomedical Applications of Crosslinked Collagen
Gu, L., Shan, T., Ma, Y.-X., Tay, F. R., & Niu, L. (2019) · Trends in Biotechnology · doi:10.1016/j.tibtech.2018.10.007 · Cited by 305
Discovery and development of the anticancer agent salinosporamide A (NPI-0052)
Fenical, W., Jensen, P. R., Palladino, M. A., Lam, K. S., Lloyd, G. K., & Potts, B. C. (2009) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2008.10.075 · Cited by 291
Kazandjian, D., Blumenthal, G. M., Chen, H.-Y., He, K., Patel, M., Justice, R., Keegan, P., & Pazdur, R. (2014) · The Oncologist · doi:10.1634/theoncologist.2014-0241 · Cited by 286
Cytarabine and neurologic toxicity.
Baker, W. J., Royer, G. L., & Weiss, R. B. (1991) · Journal of Clinical Oncology · doi:10.1200/jco.1991.9.4.679 · Cited by 285
Alpelisib: First Global Approval
Markham, A. (2019) · Drugs · doi:10.1007/s40265-019-01161-6 · Cited by 270
Dreyling, M., Morschhauser, F., Bouabdallah, K., Bron, D., Cunningham, D., Assouline, S. E., Verhoef, G., Linton, K., Thieblemont, C., Vitolo, U., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx289 · Cited by 265
Hameed, A., Al-Rashida, M., Uroos, M., Ali, S. A., Arshia, Ishtiaq, M., & Khan, K. M. (2018) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2018.1432596 · Cited by 258
Cyclin-dependent protein kinase inhibitors including palbociclib as anticancer drugs
Roskoski, R. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.03.012 · Cited by 237
Larotrectinib: First Global Approval
Scott, L. J. (2019) · Drugs · doi:10.1007/s40265-018-1044-x · Cited by 237
Concept of Hybrid Drugs and Recent Advancements in Anticancer Hybrids
Singh, A. K., Kumar, A., Singh, H., Sonawane, P., Paliwal, H., Thareja, S., Pathak, P., Grishina, M., Jaremko, M., Emwas, A.-H., et al. (2022) · Pharmaceuticals · doi:10.3390/ph15091071 · Cited by 225
Self-citationOdogwu, L., Mathieu, L., Blumenthal, G., Larkins, E., Goldberg, K. B., Griffin, N., Bijwaard, K., Lee, E. Y., Philip, R., Jiang, X., et al. (2018) · The Oncologist · doi:10.1634/theoncologist.2017-0642 · Cited by 218
Trametinib: First Global Approval
Wright, C. J. M., & McCormack, P. L. (2013) · Drugs · doi:10.1007/s40265-013-0096-1 · Cited by 206
Dabrafenib and its potential for the treatment of metastatic melanoma
Murali, R., Menzies, A. M., & Long, G. V. (2012) · Drug Design Development and Therapy · doi:10.2147/dddt.s38998 · Cited by 192
Benzimidazole Scaffold as Anticancer Agent: Synthetic Approaches and Structure–Activity Relationship
Shrivastava, N., Naim, M. J., Alam, M. J., Nawaz, F., Ahmed, S., & Alam, O. (2017) · Archiv der Pharmazie · doi:10.1002/ardp.201700040 · Cited by 189
FDA Drug Approval Summaries: Oxaliplatin
Ibrahim, A., Hirschfeld, S., Cohen, M. H., Griebel, D. J., Williams, G. A., & Pazdur, R. (2004) · The Oncologist · doi:10.1634/theoncologist.9-1-8 · Cited by 180
Novel pyridine and pyrimidine derivatives as promising anticancer agents: A review
Albratty, M., & Alhazmi, H. A. (2022) · Arabian Journal of Chemistry · doi:10.1016/j.arabjc.2022.103846 · Cited by 179
Benner, B., Good, L., Quiroga, D., Schultz, T. E., Kassem, M., Carson, W. E., Cherian, M. A., Sardesai, S., & Wesolowski, R. (2020) · Drug Design, Development and Therapy · doi:10.2147/dddt.s253232 · Cited by 177
DeRemer, D. L., Ustun, C., & Natarajan, K. (2008) · Clinical Therapeutics · doi:10.1016/j.clinthera.2008.11.014 · Cited by 172
de Claro, R. A., McGinn, K. M., Verdun, N., Lee, S.-L., Chiu, H.-J., Saber, H., Brower, M. E., Chang, C. J. G., Pfuma, E., Habtemariam, B., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2225 · Cited by 171
Copanlisib: First Global Approval
Markham, A. (2017) · Drugs · doi:10.1007/s40265-017-0838-6 · Cited by 162
Platinum anticancer drugs. From serendipity to rational design
Monneret, C. (2011) · Annales Pharmaceutiques Françaises · doi:10.1016/j.pharma.2011.10.001 · Cited by 161
Özkay, Y., Işıkdağ, İ., İncesu, Z., & Akalın, G. (2010) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2010.04.015 · Cited by 160
Ibrutinib: First Global Approval
Cameron, F., & Sanford, M. (2014) · Drugs · doi:10.1007/s40265-014-0178-8 · Cited by 159
Drugs Five Years Later: Methotrexate
WEINSTEIN, G. D. (1977) · Annals of Internal Medicine · doi:10.7326/0003-4819-86-2-199 · Cited by 158
Upadhyay, K. D., Dodia, N. M., Khunt, R. C., Chaniyara, R., & Shah, A. K. (2018) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.7b00545 · Cited by 149
Encorafenib and Binimetinib: First Global Approvals
Shirley, M. (2018) · Drugs · doi:10.1007/s40265-018-0963-x · Cited by 149
Dabrafenib: First Global Approval
Ballantyne, A. D., & Garnock-Jones, K. P. (2013) · Drugs · doi:10.1007/s40265-013-0095-2 · Cited by 146
Mocetinostat (MGCD0103): a review of an isotype-specific histone deacetylase inhibitor
Boumber, Y., Younes, A., & Garcia‐Manero, G. (2011) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2011.577737 · Cited by 137
Larkins, E. A., Blumenthal, G. M., Chen, H., He, K., Agarwal, R., Gieser, G., Stephens, O., Zahalka, E. A., Barnett-Ringgold, K., Helms, W. S., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1293 · Cited by 135
Selinexor: First Global Approval
Syed, Y. Y. (2019) · Drugs · doi:10.1007/s40265-019-01188-9 · Cited by 131
Recent advances and prospects in gemcitabine drug delivery systems
Paroha, S., Verma, J., Dubey, R. D., Dewangan, R. P., Molugulu, N., Bapat, R. A., Sahoo, P. K., & Kesharwani, P. (2020) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2020.120043 · Cited by 130
Sangani, C. B., Makawana, J. A., Zhang, X., Teraiya, S. B., Lin, L., & Zhu, H. (2014) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.01.018 · Cited by 125
Lenvatinib in Management of Solid Tumors
Hao, Z., & Wang, P. (2019) · The Oncologist · doi:10.1634/theoncologist.2019-0407 · Cited by 125
Abemaciclib: First Global Approval
Kim, E. (2017) · Drugs · doi:10.1007/s40265-017-0840-z · Cited by 124
Shah, A., Bloomquist, E. W., Tang, S. W., Fu, W., Bi, Y., Liu, Q., Yu, J., Zhao, P., Palmby, T. R., Goldberg, K. B., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2369 · Cited by 123
El‐Metwally, S. A., Abou-El-Regal, M. M., Eissa, I. H., Mehany, A. B. M., Mahdy, H. A., Elkady, H., Elwan, A., & Elkaeed, E. B. (2021) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2021.104947 · Cited by 122
Alsaif, N. A., Dahab, M. A., Alanazi, M. M., Obaidullah, A. J., Almehizia, A. A., Alanazi, M. M., Aldawas, S., Mahdy, H. A., & Elkady, H. (2021) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2021.104807 · Cited by 114
Design and synthesis of novel 1,2,3-triazole–pyrimidine–urea hybrids as potential anticancer agents
Ma, L., Wang, B., Pang, L.-P., Zhang, M., Wang, S., Zheng, Y., Shao, K., Xue, D., & Liu, H. (2015) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2014.12.087 · Cited by 111
Eldehna, W. M., Hassab, M. A. E., Abo-Ashour, M. F., Al-Warhi, T. I., Elaasser, M. M., Safwat, N. A., Suliman, H. S., Ahmed, M. F. E., Al‐Rashood, S. T., Abdel‐Aziz, H. A., et al. (2021) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2021.104748 · Cited by 109
Kurumurthy, C., Rao, P. S., swamy, B. V., Kumar, G. S., Rao, P. S., Narsaiah, B., Velatooru, L. R., Pamanji, R., & Rao, J. V. (2011) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2011.05.011 · Cited by 108
Reduction of Drug Toxicity Using Dendrimers Based on Melamine
Neerman, M. F., Chen, H., Parrish, A. R., & Simanek, E. E. (2004) · Molecular Pharmaceutics · doi:10.1021/mp049957p · Cited by 106
Afatinib—new therapy option for EGFR-mutant lung cancer
Yu, H. A., & Pao, W. (2013) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.154 · Cited by 105
Arora, S., Balasubramaniam, S., Zhang, W., Zhang, L., Sridhara, R., Spillman, D., Mathai, J. P., Scott, B., Golding, S. J., Coory, M. D., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3979 · Cited by 102
Moshikur, R. M., Chowdhury, M. R., Wakabayashi, R., Tahara, Y., Moniruzzaman, M., & Goto, M. (2019) · Journal of Molecular Liquids · doi:10.1016/j.molliq.2019.01.063 · Cited by 100
Singh, H., Walker, A. J., Amiri-Kordestani, L., Cheng, J., Tang, S., Balcazar, P., Barnett-Ringgold, K., Palmby, T. R., Cao, X., Zheng, N., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3628 · Cited by 99
Self-citationReview on supermolecules as chemical drugs
Zhou, C., Gan, L., Zhang, Y., Zhang, F., Wang, G.-Z., Jin, L., & Geng, R. (2009) · Science China Chemistry · doi:10.1007/s11426-009-0103-2 · Cited by 99
George, R. F., Samir, E. M., Abdelhamed, M. N., Abdel‐Aziz, H. A., & Abbas, S. E.-S. (2018) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2018.10.038 · Cited by 99
Kumar, R. N., Dev, G. J., Ravikumar, N., Swaroop, D. K., Debanjan, B., Bharath, G., Narsaiah, B., Jain, S. N., & Rao, A. G. (2016) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2016.04.038 · Cited by 94
Duvelisib: A 2018 Novel FDA-Approved Small Molecule Inhibiting Phosphoinositide 3-Kinases
Rodrigues, D. A., Sagrillo, F. S., & Fraga, C. A. M. (2019) · Pharmaceuticals · doi:10.3390/ph12020069 · Cited by 94
Nair, A., Reece, K. M., Donoghue, M. B., Yuan, W., Rodríguez, L., Keegan, P., & Pazdur, R. (2020) · The Oncologist · doi:10.1002/onco.13566 · Cited by 94
Barone, A. K., Chi, D.-C., Theoret, M. R., Chen, H., He, K., Kufrin, D., Helms, W. S., Subramaniam, S., Zhao, H., Patel, A., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0898 · Cited by 89
Xu, Y., Yang, Q., Liu, T., Li, K., Liu, Y., Zhu, C., Zhang, Z., Li, L., Zhang, C., Xie, M., et al. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.06.054 · Cited by 87
Olaparib: A Novel Therapy for Metastatic Breast Cancer in Patients With a BRCA1/2 Mutation
Caulfield, S. E., Christine C. Davis, P., & Byers, K. (2019) · Journal of the Advanced Practitioner in Oncology · doi:10.6004/jadpro.2019.10.2.6 · Cited by 87
Sun, N., Ren, C., Kong, Y., Zhong, H., Chen, J., Li, Y., Zhang, J., Zhou, Y., Qiu, X., Lin, H., et al. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112190 · Cited by 85
Pyridine-Ureas as Potential Anticancer Agents: Synthesis and In Vitro Biological Evaluation
El-Naggar, M. H., Almahli, H., Ibrahim, H. S., Eldehna, W. M., & Abdel‐Aziz, H. A. (2018) · Molecules · doi:10.3390/molecules23061459 · Cited by 83
Zhang, Y., Zou, J.-Y., Wang, Z., & Wang, Y. (2019) · Cancer Management and Research · doi:10.2147/cmar.s215533 · Cited by 82
Quinoxaline‐Based Scaffolds Targeting Tyrosine Kinases and Their Potential Anticancer Activity
Newahie, A. M. S. E., Ismail, N. S. M., Ella, D. A. A. E., & Abouzid, K. A. M. (2016) · Archiv der Pharmazie · doi:10.1002/ardp.201500468 · Cited by 81
Sivaramakarthikeyan, R., Iniyaval, S., Saravanan, V., Lim, W., Mai, C., & Ramalingan, C. (2020) · ACS Omega · doi:10.1021/acsomega.0c00630 · Cited by 81
Federman, N. C., & McDermott, R. (2019) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2019.1661775 · Cited by 80
The discovery and development of binimetinib for the treatment of melanoma
Tran, B., & Cohen, M. S. (2020) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2020.1746265 · Cited by 80
Al-Warhi, T. I., Sallam, A.-A. M., Hemeda, L. R., Hassab, M. A. E., Aljaeed, N., Alotaibi, O. J., Doghish, A. S., Noshy, M., Eldehna, W. M., & Ibrahim, M. H. (2022) · Pharmaceuticals · doi:10.3390/ph15101262 · Cited by 80
Abdelsalam, E. A., Zaghary, W. A., Amin, K. M., Abou-Taleb, N. A., Mekawey, A. A. I., Eldehna, W. M., Abdel‐Aziz, H. A., & Hammad, S. (2019) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2019.102985 · Cited by 79
Sana, S., Reddy, V. G., Reddy, T. S., Tokala, R., Kumar, R., Bhargava, S. K., & Shankaraiah, N. (2021) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2021.104765 · Cited by 78
Brogden, R. N., & Faulds, D. M. (1995) · Drugs & Aging · doi:10.2165/00002512-199506040-00007 · Cited by 77
Chang, J. K., Ren, H., Zhao, M., Yan, C., Zhao, W., He, Y., Zhao, Y., Zhang, H., & Qi, C. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.07.005 · Cited by 76
Lu, J. M. (2015) · Journal of Hematology & Oncology · doi:10.1186/s13045-015-0194-5 · Cited by 73
Acalabrutinib: First Global Approval
Markham, A., & Dhillon, S. (2017) · Drugs · doi:10.1007/s40265-017-0852-8 · Cited by 73
Elzahabi, H. S. A., Nossier, E. S., Khalifa, N. M., Alasfoury, R. A., & El‐Manawaty, M. A. (2018) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2018.1437729 · Cited by 73
Oskuei, S. R., Mirzaei, S., Jafari-Nik, M. R., et al. (2021) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2021.104904 · Cited by 70
Jin, X., Chen, H., Li, D., Li, A., Wang, W., & Gu, W. (2019) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2019.1605364 · Cited by 69
Selinexor for the treatment of multiple myeloma
Podar, K., Shah, J. J., Chari, A., Richardson, P. G. G., & Jagannath, S. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2019.1707184 · Cited by 68
Al‐Anazi, M., Khairuddean, M., Al-Najjar, B. O., Alidmat, M. M., Kamal, N. N. S. N. M., & Muhamad, M. (2022) · Arabian Journal of Chemistry · doi:10.1016/j.arabjc.2022.103864 · Cited by 67
Zhang, W., Fan, Y., Cai, C., Wang, J., Teng, Q., Lei, Z., Zeng, L., Gupta, P., & Chen, Z. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01097 · Cited by 65
Collier, T. L., Normandin, M. D., Stephenson, N. A., Livni, E., Liang, S. H., Wooten, D., Esfahani, S. A., Stabin, M. G., Mahmood, U., Chen, J., et al. (2017) · Nature Communications · doi:10.1038/ncomms15761 · Cited by 64
Lavacchi, D., Mazzoni, F., & Giaccone, G. (2019) · Drug Design Development and Therapy · doi:10.2147/dddt.s194231 · Cited by 64
He, Z., Qiao, H., Yang, F., Zhou, W., Gong, Y., Zhang, X., Wang, H., Zhao, B. Q., Ma, L., Liu, H., et al. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.111764 · Cited by 63
Elzahabi, H. S. A., Nafie, M. S., Osman, D. A., Elghazawy, N. H., Soliman, D. H., El‐Helby, A. A., & Arafa, R. K. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113609 · Cited by 63
Shi, L., Wu, T.-T., Wang, Z., Xue, J., & Xu, Y. (2014) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2014.07.008 · Cited by 62
Idelalisib: A Novel PI3Kδ Inhibitor for Chronic Lymphocytic Leukemia
Shah, A., & Mangaonkar, A. A. (2015) · Annals of Pharmacotherapy · doi:10.1177/1060028015594813 · Cited by 60
Zeiser, R., Andrlová, H., & Meiß, F. (2018) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-319-91442-8_7 · Cited by 60
FDA-Approved Small Molecule Compounds as Drugs for Solid Cancers from Early 2011 to the End of 2021
Sochacka-Ćwikła, A., Mą̨czyński, M., & Regiec, A. (2022) · Molecules · doi:10.3390/molecules27072259 · Cited by 59
Undeniable Pharmacological Potentials of Quinazoline Motifs in Therapeutic Medicine
Ajani, O. O., Audu, O. Y., Aderohunmu, D. V., Owolabi, F. E., & Olomieja, A. O. (2016) · American Journal of Drug Discovery and Development · doi:10.3923/ajdd.2017.1.24 · Cited by 58
Yang, D., An, B., Wei, W., Tian, L., Huang, B., & Wang, H. (2014) · ACS Combinatorial Science · doi:10.1021/co500125n · Cited by 57
Hou, J., Wan, S., Wang, G., Zhang, T., Li, Z., Tian, Y., Yu, Y., Wu, X., & Zhang, J. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.04.026 · Cited by 57
Butterworth, S., Cross, D. A. E., Finlay, M. R. V., Ward, R. A., & Waring, M. J. (2017) · MedChemComm · doi:10.1039/c7md90012k · Cited by 57
Anticancer Drug Discovery from the Marine Environment
Nastrucci, C., Cesario, A., & Russo, P. (2012) · Recent Patents on Anti-Cancer Drug Discovery · doi:10.2174/157489212799972963 · Cited by 55
Kumbhare, R. M., Dadmal, T. L., Ramaiah, M. J., Kishore, K., Valli, S. N. C. V. L. P., Tiwari, S. K., Appalanaidu, K., Rao, Y. K., & Bhadra, M. P. (2014) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2014.11.083 · Cited by 54
Singh, H., Brave, M. H., Beaver, J. A., Cheng, J., Tang, S. W., Zahalka, E. A., Palmby, T. R., Venugopal, R., Song, P., Liu, Q., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1073 · Cited by 54
Self-citationAn update of new small-molecule anticancer drugs approved from 2015 to 2020
Liang, X., Wu, P., Yang, Q., Xie, Y., He, C., Yin, L., Yin, Z., Yue, G., Zou, Y., Li, L., et al. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113473 · Cited by 54
FDA Approval Summary: Midostaurin for the Treatment of Advanced Systemic Mastocytosis
Kasamon, Y. L., Ko, C., Subramaniam, S., Ma, L., Yang, Y., Nie, L., Shord, S. S., Przepiorka, D., Farrell, A. T., McKee, A. E., et al. (2018) · The Oncologist · doi:10.1634/theoncologist.2018-0222 · Cited by 53
Anticancer activities of genistein‐topotecan combination in prostate cancer cells
Hörmann, V., Kumi-Diaka, J. K., Durity, M., & Rathinavelu, A. (2012) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2012.01576.x · Cited by 52
Wu, L., Jiang, Z., Shen, J., Yi, H., Zhan, Y.-C., Sha, M.-Q., Wang, Z., Xue, S.-T., & Li, Z. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.03.029 · Cited by 52
New Quinoline-Based Heterocycles as Anticancer Agents Targeting Bcl-2
Hamdy, R., Elseginy, S. A., Ziedan, N. I., Jones, A. T., & Westwell, A. D. (2019) · Molecules · doi:10.3390/molecules24071274 · Cited by 52
Entrectinib for the treatment of metastatic NSCLC: safety and efficacy
Bianchi, A. S., Pizzutilo, E. G., Marrapese, G., Tosi, F., Cerea, G., & Siena, S. (2020) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2020.1747439 · Cited by 52
Cihan‐Üstündağ, G., Şatana, D., Özhan, G., & Çapan, G. (2015) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.3109/14756366.2015.1024673 · Cited by 51
Romero‐Castro, A., León‐Rivera, I., Ávila-Rojas, L. C., Navarrete‐Vázquez, G., & Nieto-Rodríguez, A. (2011) · Archives of Pharmacal Research · doi:10.1007/s12272-011-0201-5 · Cited by 49
Crizotinib: A New Treatment Option for ALK -Positive Non-Small Cell Lung Cancer
O’Bryant, C. L., Wenger, S. D., Kim, M., & THOMPSON, L. A. (2013) · Annals of Pharmacotherapy · doi:10.1345/aph.1r002 · Cited by 48
Gunawardane, R. N., Nepomuceno, R. R., Rooks, A. M., Hunt, J. P., Ricono, J. M., Belli, B., & Armstrong, R. C. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0305 · Cited by 48
Design, Synthesis and Anticancer Evaluation of Novel Quinazoline-Sulfonamide Hybrids
Ghorab, M. M., Alsaid, M. S., Al-Dosari, M. S., El-Gazzar, M. G., & Parvez, M. K. (2016) · Molecules · doi:10.3390/molecules21020189 · Cited by 45
Isaac, K. M., & Mato, A. R. (2020) · Cancer Management and Research · doi:10.2147/cmar.s219570 · Cited by 45
Zirlik, K., & Veelken, H. (2018) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-319-91439-8_12 · Cited by 45
Kalra, S., Joshi, G., Kumar, M., Arora, S., Kaur, H., Singh, S., Munshi, A., & Kumar, R. (2020) · RSC Medicinal Chemistry · doi:10.1039/d0md00146e · Cited by 44
Ewes, W. A., Elmorsy, M. A., El‐Messery, S. M., & Nasr, M. N. A. (2020) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2020.115373 · Cited by 43
Antitumor activity of TZT-1027 (Soblidotin).
Watanabe, J., Minami, M., & Kobayashi, M. (2006) · PubMed · Cited by 42
Development of Novel Pyridine-Thiazole Hybrid Molecules as Potential Anticancer Agents
Ivasechko, I., Yushyn, I., Roszczenko, P., Senkiv, J., Finiuk, N. S., Lesyk, D., Holota, S. M., Czarnomysy, R., Klyuchivska, O., Khyluk, D., et al. (2022) · Molecules · doi:10.3390/molecules27196219 · Cited by 42
Design, Synthesis and Biological Evaluation of New Pyrimidine Derivatives as Anticancer Agents
Madia, V. N., Nicolai, A., Messore, A., Leo, A. D., Ialongo, D., Tudino, V., Saccoliti, F., Vita, D. D., Scipione, L., Artico, M., et al. (2021) · Molecules · doi:10.3390/molecules26030771 · Cited by 37
Ramya, P., Guntuku, L., Angapelly, S., Karri, S., Digwal, C. S., Babu, B. N., Naidu, V. G. M., & Kamal, Ä. (2018) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2018.01.070 · Cited by 35
Ranjbari, S., Behzadi, M., Sepehri, S., Aseman, M. D., Jarrahpour, A., Mohkam, M., Ghasemi, Y., Akbarizadeh, A. R., Kianpour, S., Atioğlu, Z., et al. (2020) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2020.115408 · Cited by 33
Green synthetic approaches for biologically relevant organic compounds
Jangale, A. D., & Dalal, D. S. (2017) · Synthetic Communications · doi:10.1080/00397911.2017.1369544 · Cited by 28
Eldehna, W. M., Hassan, G. S., Al‐Rashood, S. T., Alkahtani, H. M., Almehizia, A. A., & Al-Ansary, G. H. (2020) · Marine Drugs · doi:10.3390/md18040190 · Cited by 28
Role of Collagen Regulators in Cancer Treatment: A Comprehensive Review
Angre, T. D., Kumar, A., Singh, A. K., Thareja, S., & Kumar, P. (2022) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520622666220501162351 · Cited by 28
Self-citationCurrent Insights into the Role of BRAF Inhibitors in Treatment of Melanoma
Kumar, P., Singh, A. K., Kumar, A., & Thareja, S. (2022) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520622666220624164152 · Cited by 27
Self-citationSynthesis and biological evaluation of novel quinazoline-sulfonamides as anti-cancer agents
Poudapally, S., Battu, S., Velatooru, L. R., Bethu, M. S., Janapala, V. R., Sharma, S., Sen, S., Pottabathini, N., Iska, V. B. R., & Katangoor, V. (2017) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2017.03.042 · Cited by 26
Synthesis of New Pyrimidine‐Triazole Derivatives and Investigation of Their Anticancer Activities
Osmani̇ye, D., Hıdır, A., Sağlık, B. N., Levent, S., Özkay, Y., & Kaplancıklı, Z. A. (2022) · Chemistry & Biodiversity · doi:10.1002/cbdv.202200216 · Cited by 26
Bose, D. S., Idrees, M., Todewale, I. K., Jakka, N. M., & Rao, J. V. (2012) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2012.01.014 · Cited by 25
Biological activity and molecular docking studies of some new quinolines as potent anticancer agents
Köprülü, T. K., Ökten, S., Atalay, V. E., Teki̇n, Ş., & Çakmak, O. (2021) · Medical Oncology · doi:10.1007/s12032-021-01530-w · Cited by 25
Benayoun, L., Schaffer, M., Bril, R., Gingis‐Velitski, S., Segal, E., Nevelsky, A., Satchi‐Fainaro, R., & Shaked, Y. (2013) · Cancer Biology & Therapy · doi:10.4161/cbt.22630 · Cited by 21
Absorption, metabolism, excretion, and safety of [14C]almonertinib in healthy Chinese subjects
Zhou, C., Xie, L., Liu, W. Y., Zhang, L., Zhou, S., Wang, L., Chen, J., Li, H., Zhao, Y., Zhu, B., et al. (2021) · Annals of Translational Medicine · doi:10.21037/atm-21-1606 · Cited by 21
Wang, Z., Liu, L., Dai, H., Si, X., Zhang, L., Li, E., Yang, Z., Chao, G., Zheng, J., Ke, Y., et al. (2021) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2021.116265 · Cited by 17
Abu‐Zied, K. M., Mohamed, T. K., Al-Duiaj, O. K., & Zaki, M. E. A. (2014) · Heterocyclic Communications · doi:10.1515/hc-2013-0199 · Cited by 16
Nicolai, A., Madia, V. N., Messore, A., Vita, D. D., Leo, A. D., Ialongo, D., Tudino, V., Tortorella, E., Scipione, L., Taurone, S., et al. (2021) · Pharmaceuticals · doi:10.3390/ph14060564 · Cited by 12
Lou Anna Laetitia Rosine, V. O. L. I., Mamyrbekova, J. A., & Bazureau, J. P. (2020) · Open Journal of Medicinal Chemistry · doi:10.4236/ojmc.2020.103007 · Cited by 11
Metadata
- Authors
- Kumar, A., Singh, A. K., Singh, H., Vijayan, V., Kumar, D., Naik, J., Thareja, S., Yadav, J. P., Pathak, P., Grishina, M., Verma, A., Khalilullah, H., Jaremko, M., Emwas, A.-H., & Kumar, P.
- Venue
- Pharmaceuticals
- Publisher
- MDPI AG
- Published
- 2023-02-14
- Volume
- 16
- Issue
- 2
- Pages
- 299
- ISSN
- 1424-8247 (ISSN-L)
- OpenAlex
- W4320920545
- Cited by
- 363
- References
- 141
- FWCI
- 35.15
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.